TAXTOX - A retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009

Acta Oncologica

Volumn 50, Issue 7, 2011, Pages 1075-1082

  Eckhoff, Lise ^a   Nielsen, Mette ^a   Moeller, Susanne ^b   Knoop, Ann ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b The Danish Breast Cancer Cooperative Group (DBCG)   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DENMARK; DIARRHEA; DRUG DOSE REGIMEN; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPHIL COUNT; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DENMARK; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 80052914633     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.602111     Document Type: Article

References (23)

1. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;CD004421.
2. Estevez LG, Munoz M, Alvarez I, Fernandez Y, Garcia-Mata J, Ruiz-Borrego M, et al. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev 2007;33:474-83.
3. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, et al. Benefi t of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006;106:2337-44. (Pubitemid 43787656)
4. De LM, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
5. Dang C, Hudis C: Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg. Clin Breast Cancer 2006;7:51-8. (Pubitemid 43862835)
6. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: Systematic review and economic evaluation. Health Technol Assess 2007;11:1-144.
7. Lwin Z, Leighl N. Economic evaluation of docetaxel for breast cancer. Expert Opin Pharmacother 2009;10:283-90.
8. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006; 20;24:5664-71. (Pubitemid 46631307)
9. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 2002;8:1073-9. (Pubitemid 34517642)
10. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen forpatients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. (Pubitemid 46594124)
11. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23:3686-96.
12. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: Safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 2008;19:853-60. (Pubitemid 351649185)
13. Gianni L, Baselga J, Eiermann W, Guillem P, Semiglazov V, Lluch A, et al. Feasibility and tolerability of sequential doxorubicin/ paclitaxel followed by cyclophosphamide, methotrexate, and fl uorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715-21. (Pubitemid 43005921)
14. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, et al. Randomized phase 3 trial of fl uorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100:805-14. (Pubitemid 351809668)
15. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7. (Pubitemid 46623169)
16. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefi t compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-83.
17. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13. (Pubitemid 40740554)
18. Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092-9.
19. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): An open-label, phase III, randomised controlled trial. Lancet 2009;373:1681-92.
20. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 2009;27:5685-92.
21. Francis P, Crown J, Di LA, Buyse M, Balil A, Andersson M, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008;100: 121-33. (Pubitemid 351480565)
22. Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, et al. Impact of fi ve prophylactic fi lgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:6908-18.
23. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007;25:3158-67. (Pubitemid 47218066)